why choose us

First received: September 06, 2023

Clinical Trial: Evaluation of Canakinumab in High-Risk Former-Smokers

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Cigarette Smoking-Related Carcinoma

Study Type: INTERVENTIONAL


Official Title: Molecular Studies of Canakinumab in High-Risk Former-Smokers (CANIFS)

Brief Summary: This phase II trial tests the impact of canakinumab on biologic samples (buccal, nasal, and blood) from former smokers with increased risk of cancer.Canakinumab blocks the activity of a protein called interleukin-1 beta (IL-1b), an agent of the inflammatory system and is used for the treatment of different non-cancer diseases (like auto-inflammatory diseases).Giving canakinumab may block the inflammatory system and could have positive effects to reduce cancer growth.

Read more